Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study

Author(s):
Ishiguro, N.; Tanaka, Y.; Yamanaka, H.; Yoneda, T.; Ohira, T.; Okubo, N.; Genant, H.K.; Heijde, D. van der; Takeuchi, T.
Published
2019
Publication type
Article / Letter to editor
rheumatoid arthritisdenosumabbone erosionsubgroup analysisrheumatoid factoranti-cyclic citrullinated peptide antibody
Date issued
2019-06-30
Language
English
Is part of
Rheumatology (2019), Vol. 58, no. 6, p. 997-1005
hdl
1887/120951
doi
10.1093/rheumatology/key416